Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Ashish Sarraju(Center for Clinical Research (United States)), Jingwei Li(UNSW Sydney), Christopher P. Cannon(Brigham and Women's Hospital), Tara I. Chang(Stanford University), Rajiv Agarwal(Richard L. Roudebush VA Medical Center), George L. Bakris(University of Chicago), David M. Charytan(NYU Langone Health), Dick de Zeeuw(University Medical Center Groningen), Tom Greene(University of Utah), Hiddo J.L. Heerspink(University Medical Center Groningen), Adeera Levin(University of British Columbia), Bruce Neal(The George Institute for Global Health), Carol A. Pollock(The University of Sydney), David C. Wheeler(The George Institute for Global Health), Yshai Yavin(Janssen (United States)), Hong Zhang(Peking University), Bernard Zinman(University of Toronto), Vlado Perkovic(Royal North Shore Hospital), Meg Jardine(UNSW Sydney), Kenneth W. Mahaffey(Stanford Medicine)
Cited by 80Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis